Cargando…

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study

Objective: To evaluate the effect of 32-mg/d naltrexone sustained release and 360-mg/d bupropion sustained release (NB32) in overweight and obese patients with major depressive disorder (MDD). Method: Twenty-five female patients with a DSM-IV diagnosis of MDD, an Inventory of Depressive Symptomatolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	McElroy, Susan L., Guerdjikova, Anna I., Kim, Dennis D., Burns, Colleen, Harris-Collazo, Raúl, Landbloom, Ronald, Dunayevich, Eduardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Physicians Postgraduate Press, Inc. 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795584/ https://www.ncbi.nlm.nih.gov/pubmed/24171147 http://dx.doi.org/10.4088/PCC.12m01494

Ejemplares similares

Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
por: Guerdjikova, Anna I., et al.
Publicado: (2017)

A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
por: Apovian, Caroline M, et al.
Publicado: (2013)

Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
por: Pi-Sunyer, Xavier, et al.
Publicado: (2019)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
por: Dahlberg, Sarah, et al.
Publicado: (2022)

Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues
por: Wang, G-J, et al.
Publicado: (2014)

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
por: Hollander, Priscilla, et al.
Publicado: (2013)

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
por: Cho, A-Ra, et al.
Publicado: (2020)

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats
por: Scudeler, Monica Alhadas, et al.
Publicado: (2022)

Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
por: Wang, Gene-Jack, et al.
Publicado: (2018)

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives
por: Tek, Cenk
Publicado: (2016)

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Buehler, Anna M
Publicado: (2015)

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018)

Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
por: Halseth, Amy, et al.
Publicado: (2016)

Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity
por: Welling, Mila S., et al.
Publicado: (2023)

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
por: Lyu, Xuechan, et al.
Publicado: (2018)

The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy
por: le Roux, Carel W., et al.
Publicado: (2022)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures
por: Siamidi, Angeliki, et al.
Publicado: (2021)

Role of Bupropion and Naltrexone in Managing Depression With Polycystic Ovary Syndrome: A Case Report and Literature Review
por: Shah, Kaushal, et al.
Publicado: (2020)

Simultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
por: Abdel-Gawad, Sherif A., et al.
Publicado: (2018)

Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine
por: Guerdjikova, Anna I, et al.
Publicado: (2016)

Dissolution Assay of Bupropion/Naltrexone Hydrochloride Salts of Bilayer Composition Tablets Following the Development and Validation of a Novel HPLC Method
por: Apostolidi, Anna, et al.
Publicado: (2022)

Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro
por: Sager, Jennifer E., et al.
Publicado: (2016)

Pharmacological management of binge eating disorder: current and emerging treatment options
por: McElroy, Susan L, et al.
Publicado: (2012)

Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
por: McCarthy, Brian, et al.
Publicado: (2023)

Pediatric Toxidrome Simulation Curriculum: Bupropion Overdose
por: Hartford, Emily, et al.
Publicado: (2019)

Hyponatremia Associated with Bupropion
por: Kim, Chang Seong, et al.
Publicado: (2011)

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial
por: Wharton, Sean, et al.
Publicado: (2021)

Can bupropion unmask psychosis
por: Grover, Sandeep, et al.
Publicado: (2009)

Bupropion-Induced Erythema Multiforme
por: Evrensel, Alper, et al.
Publicado: (2015)

Tardive Dyskinesia Associated with Bupropion
por: Tuman, Taha Can, et al.
Publicado: (2017)

Bupropion-Induced Severe Leukocytosis
por: Jolly, Taranjeet S, et al.
Publicado: (2020)

Erythrodermic Psoriasis Exacerbated by Bupropion
por: Foss, Michael G, et al.
Publicado: (2021)

O-Benzoylnaltrexone
por: Yang, Rui, et al.
Publicado: (2013)

Asymmetric synthesis of (–)-naltrexone
por: Dongbang, Sun, et al.
Publicado: (2018)

Open Label Trial of Naltrexone Implants: Measuring Blood Serum Levels of Naltrexone
por: Colquhoun, Ross M.
Publicado: (2013)

Bupropion hydrobromide propanol hemisolvate
por: Liu, Min, et al.
Publicado: (2011)

Bupropion-Induced Diplopia in an Iranian Patient
por: Fayyazi Bordbar, Mohammad Reza, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6nkbpql3i0ol8c8dl13287u7jm